2024
Understanding the Added Value of High-Resolution CT Beyond Chest X-Ray in Determining Extent of Physiologic Impairment
Benn B, Lippitt W, Cortopassi I, Balasubramani G, Barbosa E, Drake W, Herzog E, Gibson K, Chen E, Koth L, Fuhrman C, Lynch D, Kaminski N, Wisniewski S, Carlson N, Maier L. Understanding the Added Value of High-Resolution CT Beyond Chest X-Ray in Determining Extent of Physiologic Impairment. CHEST Journal 2024, 166: 1093-1107. PMID: 38830401, DOI: 10.1016/j.chest.2024.04.031.Peer-Reviewed Original ResearchScadding stageCT featuresLung functionChest radiologistsCT scanAlpha-1 anti-trypsin deficiencyChest computed tomographyChest CT scanChest X-rayIncreasing clinical useCompare demographic featuresAssociated with FEV1Visual scoring systemSarcoidosis stagePulmonary sarcoidosisChest CTCT findingsAssociated with lung functionCT assessmentComputed tomographySarcoidosisClinical useRadiological measurementsCT measurementsScoring system
2022
Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in Preclinical Models of Pulmonary Fibrosis.
Ahangari F, Becker C, Foster DG, Chioccioli M, Nelson M, Beke K, Wang X, Justet A, Adams T, Readhead B, Meador C, Correll K, Lili LN, Roybal HM, Rose KA, Ding S, Barnthaler T, Briones N, DeIuliis G, Schupp JC, Li Q, Omote N, Aschner Y, Sharma L, Kopf KW, Magnusson B, Hicks R, Backmark A, Dela Cruz CS, Rosas I, Cousens LP, Dudley JT, Kaminski N, Downey GP. Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in Preclinical Models of Pulmonary Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2022, 206: 1463-1479. PMID: 35998281, PMCID: PMC9757097, DOI: 10.1164/rccm.202010-3832oc.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisHuman precision-cut lung slicesPrecision-cut lung slicesPulmonary fibrosisNormal human lung fibroblastsEpithelial-mesenchymal transitionHuman lung fibroblastsFibrogenic pathwaysPreclinical modelsMurine modelLung slicesSrc kinase inhibitorLung fibroblastsKinase inhibitorsAmelioration of fibrosisSelective Src kinase inhibitorHuman lung fibrosisWhole lung extractsPotential therapeutic efficacyIPF diseaseIPF treatmentLung functionInflammatory cascadeLung fibrosisAntifibrotic efficacyLongitudinal lung function and gas transfer in individuals with idiopathic pulmonary fibrosis: a genome-wide association study
Allen RJ, Oldham JM, Jenkins DA, Leavy OC, Guillen-Guio B, Melbourne CA, Ma SF, Jou J, Kim JS, Cooperative C, Fahy WA, Oballa E, Hubbard RB, Navaratnam V, Braybrooke R, Saini G, Roach KM, Tobin MD, Hirani N, Whyte MKB, Kaminski N, Zhang Y, Martinez FJ, Linderholm AL, Adegunsoye A, Strek ME, Maher TM, Molyneaux PL, Flores C, Noth I, Jenkins R, Wain LV. Longitudinal lung function and gas transfer in individuals with idiopathic pulmonary fibrosis: a genome-wide association study. The Lancet Respiratory Medicine 2022, 11: 65-73. PMID: 35985358, PMCID: PMC10077113, DOI: 10.1016/s2213-2600(22)00251-x.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisPulmonary fibrosisLung capacityAmerican Thoracic Society/European Respiratory Society guidelinesDiagnosis of IPFEuropean Respiratory Society guidelinesPotential novel therapeutic approachHealth-National HeartLongitudinal lung functionRespiratory Society guidelinesGenetic variantsNovel therapeutic approachesIncurable lung diseaseMedical Research CouncilProgressive scarringFVC declineLung functionVital capacityBlood InstituteSociety guidelinesLung diseaseNational HeartDisease progressionTherapeutic approachesSignificant associationCD38 Mediates Lung Fibrosis by Promoting Alveolar Epithelial Cell Aging.
Cui H, Xie N, Banerjee S, Dey T, Liu RM, Antony VB, Sanders YY, Adams TS, Gomez JL, Thannickal VJ, Kaminski N, Liu G. CD38 Mediates Lung Fibrosis by Promoting Alveolar Epithelial Cell Aging. American Journal Of Respiratory And Critical Care Medicine 2022, 206: 459-475. PMID: 35687485, DOI: 10.1164/rccm.202109-2151oc.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisLung fibrosisCD38 expressionAlveolar epithelial cell injuryEpithelial cell injuryEffective therapeutic strategyHuman lung parenchymaIPF lungsLung functionPulmonary fibrosisDisease progressionFibrotic lungsReal-time PCRYoung miceLung parenchymaOld miceCell injuryTherapeutic strategiesFibrosisPharmacological inactivationCD38Single-cell RNA sequencingFlow cytometryWestern blottingOld animals
2021
Machine learning implicates the IL-18 signaling axis in severe asthma
Camiolo MJ, Zhou X, Wei Q, Bittar H, Kaminski N, Ray A, Wenzel S. Machine learning implicates the IL-18 signaling axis in severe asthma. JCI Insight 2021, 6: e149945. PMID: 34591794, PMCID: PMC8663569, DOI: 10.1172/jci.insight.149945.Peer-Reviewed Original ResearchConceptsLung functionIL-18NF-κBTranscriptional hallmarksExacerbation-prone asthmaSevere asthma pathogenesisSubgroup of patientsVariable natural historySevere Asthma Research Program (SARP) cohortDownstream NF-κBMixed inflammatory processActivator protein-1 (AP-1) activationPathobiological underpinningsCorticosteroid exposureSevere asthmaAsthma clustersAsthma pathogenesisPatient morbidityInflammatory processProtein-1 activationExternal cohortLung tissuePatient clustersAP-1 activityNatural historyElevated plasma level of Pentraxin 3 is associated with emphysema and mortality in smokers
Zhang Y, Tedrow J, Nouraie M, Li X, Chandra D, Bon J, Kass DJ, Fuhrman CR, Leader JK, Duncan SR, Kaminski N, Sciurba FC. Elevated plasma level of Pentraxin 3 is associated with emphysema and mortality in smokers. Thorax 2021, 76: 335-342. PMID: 33479043, PMCID: PMC8249179, DOI: 10.1136/thoraxjnl-2020-215356.Peer-Reviewed Original ResearchConceptsAirflow obstructionPlasma levelsLung tissueEmphysema severitySmoking-related lung diseaseAssociation of lungExpiratory airflow obstructionFormer tobacco smokersLevels of PTX3PTX3 gene expressionElevated plasma levelsHyaluronic acid levelsBlood of subjectsPlasma PTX3PTX3 levelsLung functionTobacco exposureClinical outcomesTobacco smokersLung diseasePentraxin 3Predictive biomarkersPTX3 expressionLower riskDisease patterns
2020
Cathepsin B promotes collagen biosynthesis, which drives bronchiolitis obliterans syndrome
Morrone C, Smirnova NF, Jeridi A, Kneidinger N, Hollauer C, Schupp JC, Kaminski N, Jenne D, Eickelberg O, Yildirim AÖ. Cathepsin B promotes collagen biosynthesis, which drives bronchiolitis obliterans syndrome. European Respiratory Journal 2020, 57: 2001416. PMID: 33303550, DOI: 10.1183/13993003.01416-2020.Peer-Reviewed Original ResearchConceptsBronchoalveolar lavage fluidCathepsin B activityHealthy donorsLung tissueCollagen depositionB activityCathepsin BBronchiolitis obliterans syndromeProgression of BOSFluorescence resonance energy transfer-based assayPromising therapeutic targetGrowth factor-β1Cathepsin B levelsSubsequent collagen depositionBOS pathogenesisBOS patientsBOS progressionLTx patientsLymphocytic bronchiolitisObliterans syndromeLung transplantationPeribronchial fibrosisPulmonary dysfunctionLung functionMajor complications
2018
Gene correlation network analysis to identify regulatory factors in idiopathic pulmonary fibrosis
McDonough JE, Kaminski N, Thienpont B, Hogg JC, Vanaudenaerde BM, Wuyts WA. Gene correlation network analysis to identify regulatory factors in idiopathic pulmonary fibrosis. Thorax 2018, 74: 132. PMID: 30366970, PMCID: PMC6467239, DOI: 10.1136/thoraxjnl-2018-211929.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisLung functionPulmonary fibrosisExtensive pathological changesSevere lung diseaseLung Tissue Research ConsortiumCorrelation network analysisIPF cohortIPF groupLung diseaseControl subjectsUpregulated modulesT cellsImmune responsePathological changesLeucocyte activationB cellsClinical relevanceSurfactant metabolismDisease pathologyInterferon responseFibrosisBlood vesselsPathological processesGene correlation network analysis
2017
Serum Matrix Metalloproteinase-7, Respiratory Symptoms, and Mortality in Community-Dwelling Adults. MESA (Multi-Ethnic Study of Atherosclerosis)
Armstrong HF, Podolanczuk AJ, Barr RG, Oelsner EC, Kawut SM, Hoffman EA, Tracy R, Kaminski N, McClelland RL, Lederer DJ. Serum Matrix Metalloproteinase-7, Respiratory Symptoms, and Mortality in Community-Dwelling Adults. MESA (Multi-Ethnic Study of Atherosclerosis). American Journal Of Respiratory And Critical Care Medicine 2017, 196: 1311-1317. PMID: 28570100, PMCID: PMC5694831, DOI: 10.1164/rccm.201701-0254oc.Peer-Reviewed Original ResearchConceptsInterstitial lung abnormalitiesMatrix metalloproteinase-7Serum MMP-7Serum MMP-7 levelsMMP-7 levelsCommunity-dwelling adultsRespiratory symptomsOutcome dataOdds of ILAMetalloproteinase-7Serum matrix metalloproteinase-7Subclinical interstitial lung diseaseCause mortality ratesIdiopathic pulmonary fibrosisInterstitial lung diseaseLog unit incrementExertional dyspneaCause mortalityLung functionPulmonary fibrosisCox regressionLung diseasePotential confoundersPrognostic biomarkerLung abnormalities
2015
VCAM-1 is a TGF-β1 inducible gene upregulated in idiopathic pulmonary fibrosis
Agassandian M, Tedrow JR, Sembrat J, Kass DJ, Zhang Y, Goncharova EA, Kaminski N, Mallampalli RK, Vuga LJ. VCAM-1 is a TGF-β1 inducible gene upregulated in idiopathic pulmonary fibrosis. Cellular Signalling 2015, 27: 2467-2473. PMID: 26386411, PMCID: PMC4684430, DOI: 10.1016/j.cellsig.2015.09.003.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisVCAM-1IPF subjectsPulmonary fibrosisVascular cell adhesion molecule-1Lethal interstitial lung diseaseVCAM-1 protein levelsCell adhesion molecule-1Interstitial lung diseaseLungs of subjectsProtein levelsHigher plasma levelsVCAM-1 mRNAAdhesion molecule-1Pulmonary diffusion capacityHuman lung fibroblastsIPF lungsLung functionFibrotic fociVital capacityLung diseaseUnknown etiologyControl subjectsPlasma levelsCell cycle arrestOral immunotherapy with type V collagen in idiopathic pulmonary fibrosis
Wilkes DS, Chew T, Flaherty KR, Frye S, Gibson KF, Kaminski N, Klemsz MJ, Lange W, Noth I, Rothhaar K. Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis. European Respiratory Journal 2015, 45: 1393-1402. PMID: 25614165, DOI: 10.1183/09031936.00105314.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisIPF patientsPulmonary fibrosisHigh-dose cohortLow-dose cohortSerious adverse eventsPhase 1 studyProgressive lung diseaseType V collagenPrecision medicine approachMatrix metalloproteinase-7Acute exacerbationIPF trialsOral immunotherapyAdverse eventsPlacebo armLung functionPoor prognosisVital capacityLung diseaseImmune responsePatientsMetalloproteinase-7Potential efficacyMedicine approach
2014
Secreted Phosphoprotein 1 Is a Determinant of Lung Function Development in Mice
Ganguly K, Martin TM, Concel VJ, Upadhyay S, Bein K, Brant KA, George L, Mitra A, Thimraj TA, Fabisiak JP, Vuga LJ, Fattman C, Kaminski N, Schulz H, Leikauf GD. Secreted Phosphoprotein 1 Is a Determinant of Lung Function Development in Mice. American Journal Of Respiratory Cell And Molecular Biology 2014, 51: 637-651. PMID: 24816281, PMCID: PMC4224082, DOI: 10.1165/rcmb.2013-0471oc.Peer-Reviewed Original ResearchMeSH KeywordsAlveolar Epithelial CellsAnimalsAnimals, NewbornCore Binding Factor Alpha 1 SubunitFemaleGene Expression Regulation, DevelopmentalLung ComplianceMaleMice, Inbred C3HMice, Inbred C57BLMice, KnockoutOligonucleotide Array Sequence AnalysisOsteopontinPromoter Regions, GeneticPulmonary AlveoliPulmonary Disease, Chronic ObstructiveReceptor, Notch1ConceptsMicroarray analysisPhosphoprotein 1Quantitative trait lociLung functionQuantitative RT-PCR analysisDNA-protein bindingRunt-related transcription factor 2Transcription factor 2Developmental transcriptsLung developmentTrait lociNumerous genesSecreted Phosphoprotein 1Notch1 transcriptsRT-PCR analysisInsulin-like growth factor-1C3H/HeJ miceDiminished lung functionLung function developmentSPP1 promoterSPP1Growth factor-1Mean airspace chord lengthC3H/HeJGenetic variants
2013
Assessment of lung volume collapsibility in chronic obstructive lung disease patients using CT
Kundu S, Gu S, Leader JK, Tedrow JR, Sciurba FC, Gur D, Kaminski N, Pu J. Assessment of lung volume collapsibility in chronic obstructive lung disease patients using CT. European Radiology 2013, 23: 1564-1572. PMID: 23494492, PMCID: PMC3657332, DOI: 10.1007/s00330-012-2746-1.Peer-Reviewed Original ResearchConceptsPulmonary function testsUpper lobeLower lobeWhole lungLung lobesChronic obstructive lung disease patientsDisease severityGOLD categoriesObstructive lung disease patientsLung disease patientsMean lung densityTotal lung volumeAssessment of lungLobar volume changesFEV1/Lung functionExpiration volumeFunction testsGOLD classificationInspiration/expirationDisease patientsRV/Air trappingLung volumeCT examinations
2009
MMP activation peptide detection in biological samples as a diagnostic marker of idiopathic pulmonary fibrosis
Voeghtly L, Kaminski N, Oury T. MMP activation peptide detection in biological samples as a diagnostic marker of idiopathic pulmonary fibrosis. The FASEB Journal 2009, 23: 572.11-572.11. DOI: 10.1096/fasebj.23.1_supplement.572.11.Peer-Reviewed Original ResearchIdiopathic pulmonary fibrosisPulmonary fibrosisAcute exacerbationMatrix metalloproteasesMMP activationChronic interstitial lung diseaseInterstitial lung diseaseUrine of miceMechanism of clearanceActivation peptideExtracellular matrix turnoverProgressive diseaseLung functionWT miceLung diseaseUnknown etiologyDisease progressionHealthy controlsHuman patientsDiagnostic markerUrine detectionFibrosisDiseaseEarly detectionMatrix turnover
2008
Diaphragmatic paralysis: a clinical imitator of cardiorespiratory diseases.
Ben-Dov I, Kaminski N, Reichert N, Rosenman J, Shulimzon T. Diaphragmatic paralysis: a clinical imitator of cardiorespiratory diseases. Israel Medical Association Journal 2008, 10: 579-83. PMID: 18847154.Peer-Reviewed Original ResearchConceptsDiaphragmatic paralysisLung diseaseCardiorespiratory diseaseChronic obstructive lung diseaseBilateral diaphragmatic weaknessHeart-lung diseaseUpper airway obstructionLife-threatening hypoxemiaUnilateral diaphragmatic paralysisObstructive lung diseaseParenchymal lung diseaseDiaphragmatic weaknessAirway obstructionNocturnal sweatingHeart failureLung functionClinical manifestationsNocturnal wheezingSupine positionStrenuous exerciseFit menClinical imitatorPatientsDiseaseParalysis
2007
Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE, Lasky JA, Loyd JE, Noth I, Olman MA, Raghu G, Roman J, Ryu JH, Zisman DA, Hunninghake GW, Colby TV, Egan JJ, Hansell DM, Johkoh T, Kaminski N, Kim DS, Kondoh Y, Lynch DA, Müller-Quernheim J, Myers JL, Nicholson AG, Selman M, Toews GB, Wells AU, Martinez FJ, Investigators T. Acute Exacerbations of Idiopathic Pulmonary Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2007, 176: 636-643. PMID: 17585107, PMCID: PMC2094133, DOI: 10.1164/rccm.200703-463pp.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisAcute exacerbationAcute deteriorationPulmonary fibrosisBilateral radiographic opacitiesAbsence of infectionPrecipitous courseIdentifiable etiologyLung functionRespiratory statusUnknown etiologyUnidentifiable causeDiagnostic criteriaPathobiological roleExacerbationRadiographic opacitiesNatural historyRecent evidencePatientsFibrosisEtiologyInfectionPredictable declineSignificant deteriorationDeterioration